Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-05-15

Clinical Trial Update: Effect of the GSK2245035 on the Allergen-induced Asthmatic Response [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the effect of GSK2245035 on allergen-induced asthmatic response has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • GSK2245035 (GSK2245035)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Asthma | Phase 2 | Status: COMPLETED | Results posted: 2019-05-15